Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer

Y. M. Chen, R. P. Perng, K. Y. Yang, H. W. Wu, W. C. Lin, J. M. Liu, C. M. Tsai, J. Whang-Peng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. A study of tamoxifen, ifosfamide, epirubicin and cisplatin (TIEP) chemotherapy was conducted in patients with extensive-disease, small-cell lung cancer (SCLC) to assess response and toxicity. Methods. From November, 1997, to February, 1999, 11 patients were treated, including six chemo-naive patients and five patients previously treated with cisplatin plus etoposide (EP). The treatment regimen included tamoxifen 60 mg twice daily orally on days 1 to 3, ifosfamide 3 g/m2 intravenous (IV) infusion for 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2 and cisplatin 60 mg/m2 IV for 60 minutes on day 2, every 4 weeks for up to six cycles. Results. All patients were evaluated for toxicity and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 leukopenia or neutropenia occurred in all patients during treatment. Two patients (18.2%) experienced fever in association with the neutropenia, one of whom died of sepsis. Grade 3 anemia occurred in two patients (18.2%) during treatment. Toxicities other than neutropenia and anemia were limited. After two cycles of treatment, five of six chemo-naive patients (83%), and one of five previously treated patients (20%) attained a partial response (overall 54.5%, 95% confidence interval 25%-83.9%). Median survival time was 8.5 and 6 months in chemo-naive and previously EP-treated patients, respectively. The response rate and median survival time in chemo-naive patients did not improve compared with a previous study of ifosfamide plus etoposide undertaken 4 years earlier. Conclusions. Although TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with extensive-disease SCLC, it showed no remarkable benefit compared with other regimens used in chemo-naive patients. The 20% response rate and median survival of 6 months in EP-treated patients deserve further study.

Original languageEnglish
Pages (from-to)605-611
Number of pages7
JournalChinese Medical Journal (Taipei)
Volume63
Issue number8
Publication statusPublished - Sep 6 2000
Externally publishedYes

Fingerprint

Epirubicin
Ifosfamide
Small Cell Lung Carcinoma
Tamoxifen
Combination Drug Therapy
Cisplatin
Etoposide
Neutropenia
Anemia
Survival Rate
Mesna
Leukopenia
Therapeutics
Intravenous Infusions

Keywords

  • Carcinoma
  • Cisplatin
  • Epirubicin
  • Ifosfamide
  • Lung neoplasm
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer. / Chen, Y. M.; Perng, R. P.; Yang, K. Y.; Wu, H. W.; Lin, W. C.; Liu, J. M.; Tsai, C. M.; Whang-Peng, J.

In: Chinese Medical Journal (Taipei), Vol. 63, No. 8, 06.09.2000, p. 605-611.

Research output: Contribution to journalArticle

Chen, Y. M. ; Perng, R. P. ; Yang, K. Y. ; Wu, H. W. ; Lin, W. C. ; Liu, J. M. ; Tsai, C. M. ; Whang-Peng, J. / Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer. In: Chinese Medical Journal (Taipei). 2000 ; Vol. 63, No. 8. pp. 605-611.
@article{6aa6defbd486470bb4417e7c653c71c2,
title = "Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer",
abstract = "Background. A study of tamoxifen, ifosfamide, epirubicin and cisplatin (TIEP) chemotherapy was conducted in patients with extensive-disease, small-cell lung cancer (SCLC) to assess response and toxicity. Methods. From November, 1997, to February, 1999, 11 patients were treated, including six chemo-naive patients and five patients previously treated with cisplatin plus etoposide (EP). The treatment regimen included tamoxifen 60 mg twice daily orally on days 1 to 3, ifosfamide 3 g/m2 intravenous (IV) infusion for 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2 and cisplatin 60 mg/m2 IV for 60 minutes on day 2, every 4 weeks for up to six cycles. Results. All patients were evaluated for toxicity and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 leukopenia or neutropenia occurred in all patients during treatment. Two patients (18.2{\%}) experienced fever in association with the neutropenia, one of whom died of sepsis. Grade 3 anemia occurred in two patients (18.2{\%}) during treatment. Toxicities other than neutropenia and anemia were limited. After two cycles of treatment, five of six chemo-naive patients (83{\%}), and one of five previously treated patients (20{\%}) attained a partial response (overall 54.5{\%}, 95{\%} confidence interval 25{\%}-83.9{\%}). Median survival time was 8.5 and 6 months in chemo-naive and previously EP-treated patients, respectively. The response rate and median survival time in chemo-naive patients did not improve compared with a previous study of ifosfamide plus etoposide undertaken 4 years earlier. Conclusions. Although TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with extensive-disease SCLC, it showed no remarkable benefit compared with other regimens used in chemo-naive patients. The 20{\%} response rate and median survival of 6 months in EP-treated patients deserve further study.",
keywords = "Carcinoma, Cisplatin, Epirubicin, Ifosfamide, Lung neoplasm, Small-cell lung cancer",
author = "Chen, {Y. M.} and Perng, {R. P.} and Yang, {K. Y.} and Wu, {H. W.} and Lin, {W. C.} and Liu, {J. M.} and Tsai, {C. M.} and J. Whang-Peng",
year = "2000",
month = "9",
day = "6",
language = "English",
volume = "63",
pages = "605--611",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "8",

}

TY - JOUR

T1 - Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer

AU - Chen, Y. M.

AU - Perng, R. P.

AU - Yang, K. Y.

AU - Wu, H. W.

AU - Lin, W. C.

AU - Liu, J. M.

AU - Tsai, C. M.

AU - Whang-Peng, J.

PY - 2000/9/6

Y1 - 2000/9/6

N2 - Background. A study of tamoxifen, ifosfamide, epirubicin and cisplatin (TIEP) chemotherapy was conducted in patients with extensive-disease, small-cell lung cancer (SCLC) to assess response and toxicity. Methods. From November, 1997, to February, 1999, 11 patients were treated, including six chemo-naive patients and five patients previously treated with cisplatin plus etoposide (EP). The treatment regimen included tamoxifen 60 mg twice daily orally on days 1 to 3, ifosfamide 3 g/m2 intravenous (IV) infusion for 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2 and cisplatin 60 mg/m2 IV for 60 minutes on day 2, every 4 weeks for up to six cycles. Results. All patients were evaluated for toxicity and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 leukopenia or neutropenia occurred in all patients during treatment. Two patients (18.2%) experienced fever in association with the neutropenia, one of whom died of sepsis. Grade 3 anemia occurred in two patients (18.2%) during treatment. Toxicities other than neutropenia and anemia were limited. After two cycles of treatment, five of six chemo-naive patients (83%), and one of five previously treated patients (20%) attained a partial response (overall 54.5%, 95% confidence interval 25%-83.9%). Median survival time was 8.5 and 6 months in chemo-naive and previously EP-treated patients, respectively. The response rate and median survival time in chemo-naive patients did not improve compared with a previous study of ifosfamide plus etoposide undertaken 4 years earlier. Conclusions. Although TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with extensive-disease SCLC, it showed no remarkable benefit compared with other regimens used in chemo-naive patients. The 20% response rate and median survival of 6 months in EP-treated patients deserve further study.

AB - Background. A study of tamoxifen, ifosfamide, epirubicin and cisplatin (TIEP) chemotherapy was conducted in patients with extensive-disease, small-cell lung cancer (SCLC) to assess response and toxicity. Methods. From November, 1997, to February, 1999, 11 patients were treated, including six chemo-naive patients and five patients previously treated with cisplatin plus etoposide (EP). The treatment regimen included tamoxifen 60 mg twice daily orally on days 1 to 3, ifosfamide 3 g/m2 intravenous (IV) infusion for 60 minutes with mesna on day 2, epirubicin 50 mg/m2 IV bolus on day 2 and cisplatin 60 mg/m2 IV for 60 minutes on day 2, every 4 weeks for up to six cycles. Results. All patients were evaluated for toxicity and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 leukopenia or neutropenia occurred in all patients during treatment. Two patients (18.2%) experienced fever in association with the neutropenia, one of whom died of sepsis. Grade 3 anemia occurred in two patients (18.2%) during treatment. Toxicities other than neutropenia and anemia were limited. After two cycles of treatment, five of six chemo-naive patients (83%), and one of five previously treated patients (20%) attained a partial response (overall 54.5%, 95% confidence interval 25%-83.9%). Median survival time was 8.5 and 6 months in chemo-naive and previously EP-treated patients, respectively. The response rate and median survival time in chemo-naive patients did not improve compared with a previous study of ifosfamide plus etoposide undertaken 4 years earlier. Conclusions. Although TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with extensive-disease SCLC, it showed no remarkable benefit compared with other regimens used in chemo-naive patients. The 20% response rate and median survival of 6 months in EP-treated patients deserve further study.

KW - Carcinoma

KW - Cisplatin

KW - Epirubicin

KW - Ifosfamide

KW - Lung neoplasm

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0033843608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033843608&partnerID=8YFLogxK

M3 - Article

C2 - 10969446

AN - SCOPUS:0033843608

VL - 63

SP - 605

EP - 611

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 8

ER -